Corcept Therapeutics Incorporated logo

Corcept Therapeutics IncorporatedNASDAQ: CORT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

14 April 2004

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$5.25 B
0%vs. 3y high
89%vs. sector
-4%vs. 3y high
65%vs. sector
0%vs. 3y high
90%vs. sector
0%vs. 3y high
71%vs. sector

Price

regular market | 1 min ago
$50.14+$1.27(+2.59%)

Dividend

No data over the past 3 years
$182.55 M$198.02 M
$182.55 M$47.21 M

Analysts recommendations

Institutional Ownership

CORT Latest News

Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade
zacks.com04 November 2024 Sentiment: -

The average of price targets set by Wall Street analysts indicates a potential upside of 56.7% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Recent Price Trend in Corcept (CORT) is Your Friend, Here's Why
zacks.com04 November 2024 Sentiment: POSITIVE

If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy?
zacks.com01 November 2024 Sentiment: POSITIVE

Corcept (CORT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates
zacks.com30 October 2024 Sentiment: POSITIVE

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.28 per share a year ago.

5 Stocks With Recent Price Strength to Tap Wall Street Rally
zacks.com22 October 2024 Sentiment: POSITIVE

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IDR, QFIN, SEZL, CORT, FINW.

Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength?
zacks.com21 October 2024 Sentiment: NEUTRAL

Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High?
zacks.com17 October 2024 Sentiment: POSITIVE

The mean of analysts' price targets for Corcept (CORT) points to a 43% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Corcept (CORT) Is a Great Choice for 'Trend' Investors, Here's Why
zacks.com17 October 2024 Sentiment: POSITIVE

If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Corcept: Key Announcements Coming Soon
seekingalpha.com15 October 2024 Sentiment: POSITIVE

Corcept's upcoming Q4 announcements include pivotal trial results for Relacorilant in ovarian cancer, Dazucorilant in ALS, and an NDA filing for Relacorilant in Cushing's. Positive results from these trials could significantly boost CORT's revenue potential, especially in non-Cushing's applications like cancer and ALS. Corcept's academic alliances enhance its research capabilities, supporting the development of diverse cortisol modulators for various diseases.

Here's Why Investors Should Consider Buying Corcept Stock Now
zacks.com02 October 2024 Sentiment: POSITIVE

Here, we are discussing some reasons why investing in CORT stock now may turn out to be a prudent move.

  • 1(current)
  • 2
  • 3

What type of business is Corcept Therapeutics Incorporated?

Corcept Therapeutics Incorporated is an American pharmaceutical company headquartered in Menlo Park, California, specializing in the development of drugs for patients with metabolic and oncological diseases, as well as mental disorders. It was founded in 1998. The company has focused on the side effects of excess cortisol (a hormone produced by the adrenal glands), studying new compounds that can alleviate these effects. Since 2012, it has been marketing Korlym (mifepristone) for the treatment of patients suffering from Cushing's syndrome, a condition caused by excessive cortisol activity. The drug is sold exclusively in the United States through sales representatives, specialized pharmacies, and distributors. The drug is manufactured by third-party organizations such as Produits Chimiques Auxiliaires et de Synthes SA.

What sector is Corcept Therapeutics Incorporated in?

Corcept Therapeutics Incorporated is in the Healthcare sector

What industry is Corcept Therapeutics Incorporated in?

Corcept Therapeutics Incorporated is in the Biotechnology industry

What country is Corcept Therapeutics Incorporated from?

Corcept Therapeutics Incorporated is headquartered in United States

When did Corcept Therapeutics Incorporated go public?

Corcept Therapeutics Incorporated initial public offering (IPO) was on 14 April 2004

What is Corcept Therapeutics Incorporated website?

https://www.corcept.com

Is Corcept Therapeutics Incorporated in the S&P 500?

No, Corcept Therapeutics Incorporated is not included in the S&P 500 index

Is Corcept Therapeutics Incorporated in the NASDAQ 100?

No, Corcept Therapeutics Incorporated is not included in the NASDAQ 100 index

Is Corcept Therapeutics Incorporated in the Dow Jones?

No, Corcept Therapeutics Incorporated is not included in the Dow Jones index

When was Corcept Therapeutics Incorporated the previous earnings report?

No data

When does Corcept Therapeutics Incorporated earnings report?

Next earnings report date is not announced yet